Patents Examined by Sreeni Padmanabhan
  • Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders
    Patent number: 9370516
    Abstract: The present invention relates to methods of treating sleep disorders in patients comprising administration of a ghrelin receptor inverse agonist or antagonist. The invention also includes methods of treating sleep disorders comprising the administration of a pharmaceutical composition comprising a ghrelin receptor inverse agonist or antagonist and at least one pharmaceutically acceptable carrier, diluent, or excipient.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: June 21, 2016
    Assignee: Pfizer Inc.
    Inventors: William S. Denney, Margaret Jackson, Gabriele Sonnenberg
  • Use of alternan as texturizing agent in foodstuffs and cosmetics
    Patent number: 9370203
    Abstract: The invention is directed to the use of alternan as a texturizing agent, particularly as a fat or oil replacer in foodstuffs or cosmetic preparations, a homogeneous composition comprising alternan and water, the use of the homogenous composition as a texturizing agent in foodstuffs or cosmetic preparations, and foodstuffs and cosmetic preparations comprising alternan as a texturizing agent or a homogeneous composition comprising alternan.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: June 21, 2016
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Claus Frohberg, Jens Pilling
  • Sulfur derivatives as chemokine receptor modulators
    Patent number: 9371278
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: June 21, 2016
    Assignee: Allergan, Inc.
    Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Pest controlling composition and method for controlling pest
    Patent number: 9370181
    Abstract: The present invention provides a composition having an excellent controlling activity on a pest. The composition comprising a compound represented by Formula (1) and one or more carbamate compound(s) selected from Group (A) shows an excellent controlling activity on a pest. Group (A): a group consisting of alanycarb, aldicarb, aldoxycarb, bendiocarb, benfuracarb, carbaryl, carbofuran, carbosulfan, cloethocarb, ethiofencarb, fenobucarb, fenothiocarb, fenoxycarb, furathiocarb, isoprocarb, metolcarb, methomyl, methiocarb, oxamyl, pirimicarb, propoxur, XMC, thiodicarb and xylylcarb.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: June 21, 2016
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: So Kiguchi, Soichi Tanaka
  • Pyrimidinone compounds as human neutrophil elastase inhibitors
    Patent number: 9365577
    Abstract: Pyrimidinone compounds defined herein exhibit human neutrophil elastase inhibitory properties and are useful for treating diseases and conditions in which HINE is implicated.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: June 14, 2016
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Lilian Alcaraz, Robert Andrew Heald, Jonathan Mark Sutton, Elisabetta Armani, Carmelida Capaldi
  • Clenbuterol for use in treatment of autism
    Patent number: 9364450
    Abstract: Clenbuterol or its salt for use in the treatment of autism, in particular pediatric autism. Improved contact with surroundings, better concentration, improved ability to plan a specific task, improved understanding, calming, and reduced psychomotor anxiety were observed.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: June 14, 2016
    Assignees: STOWARZYSZENIE SW. CELESTYNA, KRYSTYNA KOBEL-BUYS
    Inventor: Krystyna Kobel-Buys
  • Cosmetic compositions comprising fibrous pigments
    Patent number: 9364689
    Abstract: Cosmetic compositions comprising a fibrous pigment having an average diameter greater than 0.2 microns and an average aspect ratio greater than 5, and methods of using said compositions for imparting a pigmented film on skin or imparting a lightening appearance of skin are provided. The compositions optionally comprise from 0.1 to 30% of a coloring agent, selected from pigments, lakes, and dyes. The appearance of skin to which the compositions have been topically applied as a cosmetic film possesses L*, a*, and b* color space values and angular reflection properties closer to those of natural skin than an identical composition wherein the fibrous pigment has an average aspect ratio of less than 5.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: June 14, 2016
    Assignee: Avon Products, Inc.
    Inventors: Amitabh Bansal, John R. Glynn, Jr., Prithwiraj Maitra
  • Methods of using SCD1 antagonists
    Patent number: 9358250
    Abstract: Provided herein are therapies for the treatment of pathological conditions, such as cancer, and method of using SCD1 antagonists.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: June 7, 2016
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Xiangnan Du, Jing Qing
  • Cyclopropylamines as LSD1 inhibitors
    Patent number: 9346840
    Abstract: This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: May 24, 2016
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Neil W. Johnson, Jiri Kasparec, Meagan B. Rouse, Xinrong Tian, William Henry Miller, Dominic Suarez
  • Proteasome inhibitor delanzomib for use in the treatment of lupus
    Patent number: 9340559
    Abstract: The present invention provides a method for treating lupus in a subject, comprising the step of administering to the subject Compound A.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: May 17, 2016
    Assignee: Cephalon, Inc.
    Inventors: Bruce A. Ruggeri, Matthew M. Seavey
  • Topical skin care composition
    Patent number: 9333172
    Abstract: A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: May 10, 2016
    Assignee: GALDERMA S.A.
    Inventors: Nancy Puglia, Jerry Roth, Rosario Ramirez
  • Composition containing an alkoxysilane and hyaluronic acid
    Patent number: 9333161
    Abstract: A composition comprising: at least one alkoxysilane having at least one solubilizing functional group and at least one amino substituent; at least one glycosaminoglycan chosen from hyaluronic acid; water; optionally, at least one auxiliary ingredient; and optionally, at least one volatile solvent.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: May 10, 2016
    Assignee: L'OREAL
    Inventors: Hy Si Bui, Anita Tong, Allison Elder
  • Compositions and methods for treating tuberculosis
    Patent number: 9333193
    Abstract: The invention provides for the use of antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit anti-mycobacteria activity, including the mycobacterium causing tuberculosis. Multiple compounds were synthesized and screened for anti-tuberculosis activity. Disclosed herein are a series of compounds with anti-tuberculosis activity, including six leads that completely inhibited bacterial growth at 5 micrograms per ml or less. Three of these compounds were tested to determine MIC and these ranged between 1 and 4 micrograms per ml against both drug susceptible Mycobacterium tuberculosis strains and strains that are multi-drug resistant (MDR) including XDR strains. The compounds developed are derived from parent compound nitazoxanide, which had no inhibitory activity in the stringent testing format used herein.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: May 10, 2016
    Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Paul S. Hoffman, Timothy L. MacDonald, Eric R. Houpt, Thomas E. Ballard, Jr.
  • Sulfur derivatives as chemokine receptor modulators
    Patent number: 9328067
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: May 3, 2016
    Assignee: ALLERGAN, INC.
    Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
    Patent number: 9328071
    Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: May 3, 2016
    Assignee: SANOFI
    Inventors: Matthias Schaefer, Josef Pernerstorfer, Dieter Kadereit, Hartmut Strobel, Werngard Czechtizky, L. Charlie Chen, Alena Safarova, Aleksandra Weichsel, Marcel Patek
  • Sublingual apomorphine
    Patent number: 9326981
    Abstract: The invention features methods involving the use of sublingual film formulations of apomorphine for treating Parkinson's disease. The methods involve providing the sublingual film formulation and administering the sublingual film formulation sublingually in the mouth of a subject by contacting sublingual mucosal tissue with the film.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: May 3, 2016
    Assignee: Cynapsus Therapeutics, Inc.
    Inventors: Anthony John Giovinazzo, David Bruce Hedden, Marc L. De Somer, Nathan John Bryson
  • Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor
    Patent number: 9320724
    Abstract: A method of improving cognition in a patient with Down syndrome, which entails administering one or more ?2 adrenergic receptor agonists to the patient in an amount and with a frequency effective to improve cognition of the patient as measured by contextual learning tests.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: April 26, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ahmad Salehi, Brian Mediana, Sarah Moghadam, Van Dang, Devsmita Das, Kara Martin
  • Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
    Patent number: 9308201
    Abstract: The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: April 12, 2016
    Assignee: Allergan, Inc.
    Inventors: Mohammed I. Dibas, Edward C. Hsia, John E. Donello, Daniel W. Gil
  • Treatment tool and method of gradual withdrawal from bezodiazepine dependency
    Patent number: 9301963
    Abstract: A treatment tool and method is disclosed for gradual withdrawal from benzodiazepine dependency while reducing or even minimizing withdrawal symptom intensity. An example method includes reducing emotional stress to maintain current neurotransmitter levels, stabilizing a condition with a pre-taper plan, establishing a maximum daily dosage reduction amount of benzodiazepine, based on historical data to prevent symptom escalation, reducing a current dosage of the benzodiazepine by the maximum daily dosage amount on a daily basis for up to about two weeks, and repeating establishing the maximum daily dosage reduction amount and reducing the current dosage until the daily dosage of benzodiazepine reaches zero.
    Type: Grant
    Filed: June 6, 2012
    Date of Patent: April 5, 2016
    Inventor: Julian Hill
  • Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
    Patent number: 9301934
    Abstract: Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: April 5, 2016
    Assignee: Depomed, Inc.
    Inventors: Bret Berner, Cuiping Chen